Noble Joins the Human Factors MEdical DevIce Consortium

March 9, 2021

Noble, an Aptar Pharma company, has joined the Human Factors MEdical DevIce Consortium (hfMEDIC), whose mission is to engage industry and universities in a partnership to develop safer and more effective medical devices through human-centered design.

Led by the University of Utah, the consortium also includes academic partners North Carolina State University, Rice University, San Jose State University and the University of Maryland, and industry partner AbbVie.

The global market for medical devices is approximately $436 billion, bolstered by an aging global population, according to data from hfMEDIC. The associated cost estimate of human error, based on the percentage of errors attributed to human error from the U.S. Food and Drug Administration (FDA) recall and adverse event databases, is $48 million annually, with most due to labeling design, employee error and software-use environment issues.

hfMEDIC envisions an integrated multi-disciplinary team that builds on the strengths and resources of all stakeholders (for example, patients, healthcare providers, industry, academia and regulators) to address this critical need to reduce errors through human-centered design. The Institute of Medicine has recognized that the solution must include human factors, a scientific discipline that considers the limitations and capabilities of the people who use the devices so that the design results in accurate and safe performance. These limitations can be addressed by bringing together the expertise and resources of universities and industries, which is the purpose of hfMEDIC.

Noble, a world leader in providing drug delivery training device solutions for biopharmaceutical companies and original equipment manufacturers, recently expanded its services to include Human Factors Engineering (HFE). In doing so, Noble aims to better help its customers meet the needs of their patients by advancing the development and testing of self-administered medical products to optimize safety and efficacy while minimizing use errors and the risk of adverse events. The benefits of Noble’s Human Factors Plus service offerings include producing easier-to-use devices, better patient understanding of how the devices operate, more effective and efficient training, improved patient compliance and medical outcomes, and the reduced risk of use error, product complaints and recalls.

 

“hfMEDIC is doing important work to connect the needs of the industry with the expertise of a network of researchers,” said Tim McLeroy, Noble’s executive director of marketing and patient services. “We’re honored to be a part of this consortium and serve as a consulting resource for medical device manufacturers looking to improve usability and safety of their products.”

 

SourceNoble.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version